Optimal Post recombinant Tissue plasminogen activator (Tpa-Iv) Monitoring in Ischemic Stroke

Not Applicable

Recruiting

• Conditions: Acute ischaemic stroke patients; Stroke - Ischaemic; Neurological - Other neurological disorders

• Registration Number: ACTRN12619001556134
• Lead Sponsor: The George Institute for Global Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-11-12
• Last Update Posted: 13 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 7200

Inclusion Criteria

•Adults (age more than 18 years);
•Diagnosis of AIS and have been given intravenous (IV) bolus infusion of rtPA;
•Clinically stable with mild-moderate neurological deficit (e.g. National Institutes of Health Stroke Scale [NIHSS] score less than 10) within 2 hours post IV tPA bolus dose in the opinion of the treating clinician
•Provide informed consent (or via an appropriate proxy, according to local requirements) and remain in follow-up for 90 days

Exclusion Criteria

•Definite contraindication for less intense monitoring, in the opinion of the treating clinician( i.e needs monitoring of co-morbid conditions such as renal failure, palliative care, ICU admission);
•Immediate transfer for medical treatment (e.g. for haemodialysis) or surgery (e.g. carotid endarterectomy, hematoma evacuation) where adherence to less-intense monitoring is not possible.

Study & Design

• Study Type: Interventional
• Study Design: Not specified